News Contact Us

Zymeworks partners with Ibrance and initiates Phase 2 trial

Author : Saipriya Iyer | Published Date : 2020-01-14 

Zymeworks Inc., a Vancouver based clinical stage biopharmaceutical company that develops multifunctional therapeutics, has reportedly announced the commencement of Phase 2 trial that assesses ZW25 combination therapy. The company also announced that it has reached consensus on an agreement with Pfizer, a renowned pharmaceutical corporation, which advances the study.

ZW25 by Zymeworks, which is a HER2-targeted bispecific antibody, is being assessed along with Ibrance, which is an oral CDK4/6 inhibitor developed by Pfizer, and fulvestrant hormone therapy in patients for previously treated metastatic and/or locally advanced HER2+ and HR+ breast cancer.

Furthermore, Pfizer will provide palbociclib and Zymeworks will be sponsoring the study.

The new Phase 2 clinical stage trial is an open-label, multicenter, and a two-part study. First part of the study will be evaluating the tolerability and safety of ZW25 coupled with fulvestrant and palbociclib and detecting the RD (recommended doses) of palbociclib and ZW25.

The second part of the study will be evaluating anti-tumor activity at the recommended doses level. The trail would enroll around 76 patients at the sites across the U.S. and Canada, further expansion to Spain is also being planned.

About ZW25:

ZW25 is being assessed at both Phase 1 and Phase 2 clinical stage trials throughout South Korea and North America.  ZW25 is based on the Azymetric™ platform by Zymeworks and is an antibody that is bispecific. It can bind two non-overlapping epitopes of HER2 simultaneously, a process called as biparatopic binding. Zymeworks is formulating ZW25 to be a HER2-targeted option for treating patients with tumors which express HER2.

About Zymeworks Inc.:

Zymeworks is a Vancouver based clinical stage biotechnology company that develops protein therapeutics for treating cancer patients and other inflammatory and autoimmune diseases. The firm is also developing a deep preclinical pipeline in several therapeutic areas as well as in immune-oncology. Additionally, the therapeutic platforms are being leveraged by various strategic partnerships with nearly nine biopharmaceutical companies.

Source credit: https://www.nasdaq.com/articles/zymeworks-initiates-phase-2-trial-evaluating-zw25-in-combination-with-ibrance-2020-01-12

About Author

Saipriya Iyer

Saipriya Iyer

Saipriya Iyer presently works as a content developer for fractovia.org. Having dabbled with the domain of content creation for nearly half a decade, she now boasts of an enviable portfolio, holding substantial experience in penning down pieces related to technology, finance, and a wide spectrum of other industry verticals. A qualified computer engineering graduate from the University of Pune, Saipriya can often be found leveraging her knowledge of software technology and electronics in her write-ups. She can be contacted at- [email protected] | https://twitter.com/saipriya_i

Related News

TWU accuses Qantas of inactivity as more worker test COVID-19 positive

Published Date: 2020-04-02         Author: Saipriya Iyer

The union for airline baggage holders, TWU (Transport Workers’ Union), has reportedly accused Qantas Airways, the largest Airline network of Australia, of not ensuring worker safety against COVID-19 after the company’s baggage handlers tested positive for coronavirus. The Union stated... Read More

Houseparty to offer $1M reward to anyone providing proof of sabotage

Published Date: 2020-04-01         Author: Saipriya Iyer

Houseparty, a social networking service, has recently announced a $1 million reward to anyone who can uncover a commercial smear campaign that spread rumors alleging cyber breach of other services. The company has been purchased from its creator by Fortnite developer, Epic Games, in 2019. The sit... Read More

Ever Harmonic to acquire CCO’s Clear Media stake for US$253Mn

Published Date: 2020-03-31         Author: Saipriya Iyer

Clear Channel Outdoor Holdings Inc. (CCO), one of the leading outdoor advertising companies, has reportedly inked an agreement with Ever Harmonic Global Limited, under which it would sell its 50.91% stake in China-based media company, Clear Media Ltd. For the record, Ever Harmonic is fully owned ... Read More

© 2020 Fractovia. All Rights Reserved